NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions

Postherpetic NeuralgiaPain

Interventions

DRUG

V116517 50-mg tablets

Taken orally twice daily

DRUG

V116517 30-mg tablets

Taken orally twice daily

DRUG

Pregabalin capsules

1-2 capsules taken orally twice daily

DRUG

Placebo

Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily

Trial Locations (28)

27609

Investigational Site, Raleigh

28204

Investigational Site, Charlotte

30033

Investigational Site, Decatur

32444

Investigational Site, Lynn Haven

32720

Investigational Site, DeLand

32765

Investigational Site, Oviedo

32806

Investigational Site, Orlando

33161

Investigational Site, North Miami

33351

Investigational Site, Sunrise

33410

Investigational Site, Palm Beach Gardens

33486

Investigational Site, Boca Raton

33716

Investigational Site, St. Petersburg

33916

Investigational Site, Fort Myers

34205

Investigational Site, Bradenton

34233

Investigational Site, Sarasota

48025

Investigational Site, Bingham Farms

48650

Investigational Site, Pinconning

48706

Investigational Site, Bay City

60634

Investigational Site, Chicago

66206

Investigational Site, Prairie Village

78731

Investigational Site, Austin

84106

Investigational Site, Salt Lake City

85704

Investigational Site, Tucson

87108

Investigational Site, Albuquerque

89123

Investigational Site, Las Vegas

91606

Investigational Site, North Hollywood

92037-7651

Investigational Site, La Jolla

02740

Investigational Site, New Bedford

All Listed Sponsors

lead

Purdue Pharma LP

INDUSTRY